Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PF-06835919 in hepatic impairment
NCT04193436Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of PF-06835919 in non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinite Time at Day 1, Maximum Plasma Concentration at Day 1 and 3 more. Started Jan 2020; status: completed.
02
Drugs
PF-06835919
03
Conditions
non-alcoholic fatty liver disease (NAFLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04193436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193436.